Shots:

• The preclinical results showed that the combination JAB-21822 + Cetuximab can improve the anti-tumor activity of JAB-21822 in CRC tumor models, make tumor regression, and delay tumor re-growth after the cessation of using the drug
• Jacobio plans to initiate a P-I/II, open-label, multi-center, dose-escalation, and expansion clinical trial in China to assess the safety, tolerability, and preliminary efficacy of the combination therapy in KRAS G12C mutant patients with advanced CRC
• JAB-21822 is approved for 5 clinical trials in China and the US, which includes monothx and combination therapies (with either PD-1 Ab or Cetuximab) to treat KRAS G12C advanced solid tumors mutant patients including NSCLC and colorectal cancer

Ref: Businesswire | Image: Jacobio